Kim JH, Joo JK, Ryu SY, Kim HG, Lee JH, Kim DY. Clinicopathological features of patients with middle third gastric carcinoma. World J Gastrointest Oncol 2016; 8(4): 410-415 [PMID: 27096036 DOI: 10.4251/wjgo.v8.i4.410]
Corresponding Author of This Article
Dong Yi Kim, MD, Professor, Division of Gastroenterologic Surgery, Department of Surgery, Chonnam National University Medical School, Hakdong, Donggu, Gwangju 501-757, South Korea. dockim@jnu.ac.kr
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Apr 15, 2016; 8(4): 410-415 Published online Apr 15, 2016. doi: 10.4251/wjgo.v8.i4.410
Clinicopathological features of patients with middle third gastric carcinoma
Jin Hong Kim, Jae Kyoon Joo, Seong Yeob Ryu, Ho Gun Kim, Jae Hyuk Lee, Dong Yi Kim
Jin Hong Kim, Jae Kyoon Joo, Seong Yeob Ryu, Ho Gun Kim, Dong Yi Kim, Division of Gastroenterologic Surgery, Department of Surgery, Chonnam National University Medical School, Gwangju 501-757, South Korea
Jae Hyuk Lee, Department of Pathology, Chonnam National University Medical School, Gwangju 501-757, South Korea
Author contributions: Kim JH performed the research and wrote the paper; Joo JK and Kim HG designed the research; Ryu SY contributed to the analysis; Lee JH provided clinical advice and performed the research; Kim DY conceived this research and supervised the report.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the Chonnam National University Hospital.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: We have no financial relationships to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dong Yi Kim, MD, Professor, Division of Gastroenterologic Surgery, Department of Surgery, Chonnam National University Medical School, Hakdong, Donggu, Gwangju 501-757, South Korea. dockim@jnu.ac.kr
Telephone: +82-62-2206450 Fax: +82-62-2271635
Received: January 5, 2016 Peer-review started: January 5, 2016 First decision: January 30, 2016 Revised: February 22, 2016 Accepted: March 14, 2016 Article in press: March 16, 2016 Published online: April 15, 2016 Processing time: 85 Days and 7.7 Hours
Abstract
AIM: To compared the prognosis of middle third gastric carcinoma (MGC) patients with those of patients with proximal/distal gastric carcinoma (PGC/DGC).
METHODS: Of 3299 patients diagnosed with gastric carcinoma who underwent surgery at our hospital over a 15-year period, 919 (27.9%) were diagnosed with MGC. For each patient, the following information was obtained from hospital records: Age, sex, tumor size, depth of invasion, histologic type, nodal involvement, extent of lymph node dissection, hepatic metastasis, peritoneal dissemination, stage at initial diagnosis, operative type, curability, and survival rate.
RESULTS: T1 category tumors were more common in patients with MGC than in patients with PGC (P < 0.001). Tumor stage (stage I), N category (N0), and T category (T1) significantly influenced the 5-year survival rates for patients with curatively resected tumors. A multivariate analysis showed that age, tumor size, serosal invasion, lymph node metastasis, and curability were significant predictors of survival in patients with MGC. The survival rate for MGC patients was similar to that for PGC/DGC patients (52.8% vs 44.4%/51.4%, P = 0.1138). The 5-year survival rate for MGC patients with curative resection was higher than that for MGC patients with non-curative resection (62.9% vs 8.7%, P < 0.001).
CONCLUSION: These results indicate that tumor location did not affect the prognosis. Curative resection is important for improving the prognosis of patients with MGC.
Core tip: The clinicopathological features of the patients with middle third gastric carcinoma (MGC) were reviewed retrospectively. Tumor location did not affect the prognosis. When the MGC group was divided into patients with or without curative resection, the survival rates were higher for patients with curative resection. Therefore, curative resection is important for improving the prognosis of patients with MGC.
